Neoplasms of the exocrine pancreas

Greenfield's Surgery: Scientific Principles and Practice: Fifth Edition

Volumn , Issue , 2012, Pages 837-856

  Nakeeb, Attila ^a,b   Lillemoe, Keith D ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84863695557     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (51)

1. American Cancer Society. Cancer Statistics, 2009. CA Cancer J Clin 2009;59:225-249.
2. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas 616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4:567.
3. Yeo CJ, Cameron JL. Pancreatic cancer. Curr Probl Surg 1999;36:61.
4. Chari ST, Leibson CL, Rabe KG, et al. Probability of pancreatic cancer following diabetes: a population based study. Gastroenterology 2005;129:504-511.
5. Brune KA, Kliein AP. Familial pancreatic cancer. In: Lowy Am, Leach SD, Philip PA, eds. Pancreatic Cancer. New York: Springer Science + Buisness; 2008:65-79.
6. Hruban RH. Pancreatic cancer: from genes to patient care. J Gastrointest Surg 2001;5:583.
7. Wilentz RE, Hruban RH. Pathology of cancer of the pancreas. Surg Oncol Clin North Am 1998;7:43.
8. Takaori K, Hruban RH, Maitra A, et al. Pancreatic intraepithelial neoplasia. Pancreas 2004;28:257.
9. Schmidt CM, Matos JM, Bentrem DJ, et al. Acinar cell carcinoma of the pancreas in the United States: prognostic factors and comparison to ductal adenocarcinoma. J Gastrointest Surg 2008;12:2078-2086.
10. Tseng JF, Warshaw AL, Sahani DV, et al. Serous cystadenoma of the pancreas: tumor growth rates and recommendations for treatment. Ann Surg 2005:242:413-419.
11. Sohn TA, Yeo CJ, Cameron JL, et al. Intraductal papillary mucinous neoplasms of the pancreas an updated experience. Ann Surg 2004;239:788.
12. Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2005;6:17-32.
13. Ritts RE, Pitt HA. CA 19-9 in pancreatic cancer. Surg Oncol Clin North Am 1998;7:93.
14. Pisters PWT, Lee JE, Vauthey, et al. Laparoscopy in the staging of pancreatic cancer. Br J Surg 2001;88:325.
15. Dye CE, Waxman I. Endoscopic ultrasound. Gastroenterol Clin North Am 2002;31:863.
16. Conlon KC, Dougherty E, Klimstra DS, et al. The value of minimal access surgery in the staging of patients with potentially resectable peripancreatic malignancy. Ann Surg 1996;223:134.
17. Barreiro CJ, Lillemoe KD, Koniaris LG, et al. Diagnostic laparoscopy for periampullary and pancreatic cancer: what is the true benefit? J Gastrointest Surg 2002;6:75.
18. Kausch W. Das Carcinom der Papilla Duodeni and seine radikale Entfeinung. Beitragezur Klinische Chirurgie 1912;78:439.
19. Whipple AO, Parsons WB, Mullins CR. Treatment of carcinoma of the ampulla of Vater. Ann Surg 1935;102:763.
20. Pedrazzoli S, DiCarlo V, Dionigi R, et al. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg 1998;228:508-517.
21. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg 2002;236:355.
22. Nimura Y, Nagino M, Kato H, et al. Regional vs extended lymph node dissection in radical pancreaticoduodenectomy for pancreatic cancer. A multicenter randomized controlled trial. HPB (Oxford) 2004;6 (suppl 1):2.
23. Farnell MB, Pearson RK, Sarr MG, et al. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005;138:618-630.
24. Traverso LW, Longmire WP Jr. Preservation of the pylorus in pancreaticoduodenectomy. Surg Gynecol Obstet 1978;146:959.
25. Kozuschek W, Reith HB, Waleczek H, et al. A comparison of long term results of the standard Whipple procedure and the pylorus preserving pancreatoduodenectomy. J Am Coll Surg 1994;178:443.
26. Takada T, Yasuda H, Amano H, et al. Results of a pylorus-preserving pancreatoduodenectomy for pancreatic cancer: a comparison with results of the Whipple procedure. Hepatogastroenterology 1997;44:1536.
27. Tran KT, Smeenk HG, van Eijck CH, et al. Pylorus-preserving pancreaticoduodenectomy versus standard Whipple procedure a prospective randomized multicenter analysis of 170 patients with pancreatic and periampullary tumors. Ann Surg 2004;240:738.
28. Kooby D, Gillespie T, Bentrem D, et al. Left-sided pancreatectomy: a multicenter comparison of laparoscopic and open approaches. Ann Surg 2008;248:438-446.
29. Palanivelu C, Jani K, Senthilnathan P, et al. Laparoscopic pancreaticoduodenectomy: technique and outcomes. J Am Coll Surg 2007;205:222-230.
30. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas: 201 patients. Ann Surg 1995;221:721-733.
31. Richter A, Neidergethmann M, Sturm JW, et al. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg 2003;27:324.
32. Schmidt CM, Powell ES, Yiannoutsos CT, et al. Pancreaticoduodenectomy: a 20-year experience in 516 patients. Arch Surg 2004;139:718.
33. Sosa JA, Bowman HM, Gordon TA, et al. Importance of hospital volume in the overall management of pancreatic cancer. Ann Surg 1998;228:320.
34. Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 2006;10:1199-1210.
35. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987;59:2006-2010.
36. Kinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullar region. Ann Surg 1999;230:776.
37. Neoptolemos JP, Stocken DD, Freiss H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200.
38. Regine WF, Winter KW, Abrams R, et al. RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma. J Clin Oncol 2006;24(18 S pt 1): abstract 4007.
39. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007;297:267-277.
40. Spitz FR, Abbruzzese JL, Lee JE, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997;15:928.
41. Hoffman JP, Lipsitz S, Pisansky T, et al. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1998;16:317-323.
42. Pisters PW, Wolff RA, Janjan NA, et al. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. J Clin Oncol 2002;20:2537.
43. Wolff RA, Evans DB, Crane CH. Initial results of preoperative gemcitabine-based chemoradiation for resectable pancreatic adenocarcinoma [abstract]. Proc Am Soc Clin Oncol 2002;21:130.
44. Talamonti MS, Small W Jr, Mulcahy MF, et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 2006;13:150-158.
45. Sohn TA, Lillemoe KD, Cameron JL, et al. Surgical palliation of unresectable periampullary carcinoma in the 1990s. J Am Coll Surg 1999;188:658.
46. Sarr MG, Cameron JL. Surgical management of unresectable carcinoma of the pancreas. Surgery 1982;91:123.
47. Lillemoe KD, Cameron JL, Hardacre JM, et al. Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? Ann Surg 1999;230:322.
48. Van Heek NT, De Castro SM, van Eijck CH, et al. The need for a prophylactic gastrojejunostomy for unresectable periampullary cancer: a prospective randomized multicenter trial with special focus on assessment of quality of life. Ann Surg 2003;238:894.
49. Lillemoe KD, Cameron JL, Kaufman HS, et al. Chemical splanchnicectomy in patients with unresectable pancreatic cancer: a prospective randomized trial. Ann Surg 1993;217:447.
50. Burris HA, Moore MJ, Anderson J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403.
51. Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU refractory pancreas cancer. Ann Oncol 1996;7:347.